Oryzon Genomics S.A. (BME:ORY)

Market Cap	252.33M
Revenue (ttm)	7.36M
Net Income (ttm)	-2.76M
Shares Out	78.85M
EPS (ttm)	-0.04
PE Ratio	n/a
Forward PE	246.44
Dividend	n/a
Ex-Dividend Date	n/a

Volume	296,084
Average Volume	730,445
Open	3.275
Previous Close	3.250
Day's Range	3.190 - 3.275
52-Week Range	1.400 - 4.020
Beta	0.49
RSI	52.59
Earnings Date	Feb 27, 2026

About Oryzon Genomics

Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS (central nervous system) disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 47
• Stock Exchange: Madrid Stock Exchange
• Ticker Symbol: ORY

Financial Performance

In 2024, Oryzon Genomics's revenue was $7.62 million, a decrease of -51.43% compared to the previous year's $15.69 million. Losses were -$3.79 million, 2.39% more than in 2023.

Financial numbers in USD